Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gains from Investment Securities (2016 - 2024)

Historic Gains from Investment Securities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 9 years, with Q4 2024 value amounting to $945000.0.

  • Viridian Therapeutics, Inc.\DE's Gains from Investment Securities changed N/A to $945000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $496000.0, marking a year-over-year increase of 170000.0%. This contributed to the annual value of $496000.0 for FY2024, which is 170000.0% up from last year.
  • According to the latest figures from Q4 2024, Viridian Therapeutics, Inc.\DE's Gains from Investment Securities is $945000.0.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Gains from Investment Securities peaked at $945000.0 during Q4 2024, and registered a low of -$449000.0 during Q3 2024.
  • Its 4-year average for Gains from Investment Securities is $29416.7, with a median of -$5000.0 in 2021.
  • Data for Viridian Therapeutics, Inc.\DE's Gains from Investment Securities shows a peak YoY increase of 85555.56% (in 2020) and a maximum YoY decrease of 32500.0% (in 2020) over the last 5 years.
  • Viridian Therapeutics, Inc.\DE's Gains from Investment Securities (Quarter) stood at -$1000.0 in 2020, then crashed by 100.0% to -$2000.0 in 2021, then skyrocketed by 50.0% to -$1000.0 in 2023, then skyrocketed by 94600.0% to $945000.0 in 2024.
  • Its last three reported values are $945000.0 in Q4 2024, -$449000.0 for Q3 2024, and -$1000.0 during Q2 2023.